In October 2005, Control Delivery was acquired by the Australian firm pSivida, a developer of a new biomaterial, nanostructured porous silicon, for multiple potential applications in healthcare with a core focus on drug delivery. Control Delivery Systems (CDS)is a drug delivery company developing and manufacturing implantable sustained-release pharmasurgical devices designed to treat patients with severe and chronic diseases more effectively and safely. Through the company's proven state-of-the-art technology, patients benefit from precise delivery of drugs to the locally affected area at a controlled release rate, enabling long-term effective results and fewer side effects than drugs taken systemically. CDS continues to discover and develop therapeutic solutions for severely debilitating or life-threatening diseases with few effective treatments. Currently, CDS's principal areas of focus are blinding ophthalmic diseases, severe osteoarthritis and post-surgical pain management.
